Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer
Version 2 2024-06-19, 00:50Version 2 2024-06-19, 00:50
Version 1 2021-01-12, 16:04Version 1 2021-01-12, 16:04
conference contribution
posted on 2024-06-19, 00:50authored byAnuradha Vasista, Andrew Martin, Nick Pavlakis, Katrin M Sjoquist, Stephanie Snow, Derek Jonker, Yu Jo Chua, Richard Epstein, Tony Bonaventura, Mustafa Khasraw, Suresh Varma, Nimit Singhal, David Ransom, Francine Aubin, Ronald Burkes, Howard Lim, Frederic Lemay, Stephen Begbie, Martin Stockler, Belinda Kiely
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer